Document And Entity Information
Document And Entity Information - shares | 9 Months Ended | |
Sep. 30, 2018 | Nov. 14, 2018 | |
Document Information [Line Items] | ||
Entity Registrant Name | CannaMED Enterprises, Inc. | |
Entity Central Index Key | 1,623,016 | |
Current Fiscal Year End Date | --12-31 | |
Entity Filer Category | Non-accelerated Filer | |
Entity Current Reporting Status | Yes | |
Entity Emerging Growth Company | false | |
Entity Small Business | true | |
Entity Common Stock, Shares Outstanding (in shares) | 3,500,000 | |
Document Type | 10-Q | |
Document Period End Date | Sep. 30, 2018 | |
Document Fiscal Year Focus | 2,018 | |
Document Fiscal Period Focus | Q3 | |
Amendment Flag | false |
Condensed Balance Sheets (Curre
Condensed Balance Sheets (Current Period Unaudited) - USD ($) | Sep. 30, 2018 | Dec. 31, 2017 |
ASSETS | ||
Prepaid expenses | $ 1,900 | $ 2,500 |
TOTAL ASSETS | 1,900 | 2,500 |
LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
Accounts payable and accrued expenses | 750 | 1,080 |
Related party payable | 62,264 | 40,504 |
TOTAL LIABILITIES | 63,014 | 41,584 |
STOCKHOLDERS’ DEFICIT | ||
Preferred stock, $0.0001 par value, 20,000,000 shares authorized, none issued and outstanding as of September 30, 2018 and December 31, 2017, respectively | ||
Common stock, $0.0001 par value, 100,000,000 shares authorized, 3,500,000 issued and outstanding as of September 30, 2018 and December 31, 2017, respectively | 350 | 350 |
Discount on common stock | (350) | (350) |
Additional paid in capital | 21,730 | 21,730 |
Accumulated deficit | (82,844) | (60,814) |
Total Stockholders’ Deficit | (61,114) | (39,084) |
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT | $ 1,900 | $ 2,500 |
Condensed Balance Sheets (Cur_2
Condensed Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares | Sep. 30, 2018 | Dec. 31, 2017 |
Preferred stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 |
Preferred stock, shares authorized (in shares) | 20,000,000 | 20,000,000 |
Preferred stock, shares issued (in shares) | 0 | 0 |
Preferred stock, shares outstanding (in shares) | 0 | 0 |
Common stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 |
Common stock, shares authorized (in shares) | 100,000,000 | 100,000,000 |
Common stock, shares issued (in shares) | 3,500,000 | 3,500,000 |
Common stock, shares outstanding (in shares) | 3,500,000 | 3,500,000 |
Condensed Statements of Operati
Condensed Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2018 | Sep. 30, 2017 | Sep. 30, 2018 | Sep. 30, 2017 | |
REVENUES | ||||
COST OF REVENUES | ||||
GROSS PROFIT | ||||
Operating expenses | 3,850 | 4,352 | 22,030 | 22,728 |
TOTAL OPERATING EXPENSES | (3,850) | (4,352) | (22,030) | (22,728) |
LOSS FROM OPERATIONS | (3,850) | (4,352) | (22,030) | (22,728) |
LOSS BEFORE PROVISION FOR INCOME TAXES | (3,850) | (4,352) | (22,030) | (22,728) |
Provision for income taxes | 0 | 0 | 0 | |
NET LOSS | $ (3,850) | $ (4,352) | $ (22,030) | $ (22,728) |
NET LOSS PER SHARE OF COMMON STOCK - Basic and diluted (in dollars per share) | $ (0.01) | $ (0.01) | ||
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING - Basic and diluted (in shares) | 3,500,000 | 3,500,000 | 3,500,000 | 3,500,000 |
Condensed Statements of Cash Fl
Condensed Statements of Cash Flows (Unaudited) - USD ($) | 9 Months Ended | |
Sep. 30, 2018 | Sep. 30, 2017 | |
OPERATING ACTIVITIES: | ||
Net loss | $ (22,030) | $ (22,728) |
Changes in Operating Assets and Liabilities | ||
Prepaid expenses | 600 | (4,000) |
Accrued liability | (330) | |
Net cash used in operating activities | (21,760) | (26,728) |
INVESTING ACTIVITIES: | ||
Net cash used in investing activities | ||
FINANCING ACTIVITIES: | ||
Proceeds from related party payable | 21,760 | 26,728 |
Net cash provided by financing activities | 21,760 | 26,728 |
Net increase (decrease) in cash | ||
Cash at beginning of period | ||
Cash at end of period | ||
Supplemental disclosure of cash flow information: | ||
Cash paid for interest | ||
Cash paid for income tax |
Note 1 - Basis of Presentation
Note 1 - Basis of Presentation and Organization | 9 Months Ended |
Sep. 30, 2018 | |
Notes to Financial Statements | |
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] | NOTE 1 Nature of Operations and Background CannaMED Enterprises, Inc. (“CannaMED” or “the Company”) was incorporated on September 25, 2014 not 1934. 351 368 1986, During the period covered by this report, the Company located such a target and began the process to effect a change in control. On August 24, 2015, 1. The officers and directors of Redwood Valley, James Cassidy and James McKillop, entered into a Share Purchase Agreement (the “SPA”) pursuant to which they entered into an agreement to sell an aggregate of 19,500,000 $75,000. 98% 7% 2. The Company redeemed and cancelled an aggregate of 19,500,000 20,000,000 $.0001 3. Mikhail Artamonov was named President, Secretary and Chief Financial Officer of the Company. He now serves as the Chief Executive Officer, Secretary, Chief Financial Officer and Director of the Company. On August 25, 2015, 3,000,000 86% 3,500,000 The Company envisions to initially enter into joint ventures or acquire partial ownership in: ● a laboratory for medical cannabis testing, a pharmacy to perform research; ● a pharmacy to perform research and development of the newest medical cannabis formulations; ● a clinical practice to establish the network dispensaries; ● a packaging company; ● a research facility; and ● real estate to establish the foundation for the growing network Basis of Presentation The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Intercompany accounts and transactions have been eliminated. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that may Income Taxes CannaMED accounts for income taxes in accordance with ASC 740, 740” not ASC 740 740 not not Cash and Cash Equivalents Cash and cash equivalents includes all highly liquid instruments with an original maturity of six September 30, 2018. not September 30, 2018 December 31, 2017. Concentration of Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high quality banking institutions. The Company did not September 30, 2018 December 31, 2017. Fair Value of Financial Instruments The Company adopted ASC 820, 820 820 three three ● Level 1 ● Level 2 ● Level 3 The carrying value of cash, accounts payables and accrued expenses approximates their fair values due to their short-term maturities at September 30, 2018 December 31, 2017. Revenue Recognition Effective January 1, 2018, 606, Revenue from Contracts with Customers, 606 606, five no Net Loss Per Share Basic net loss per share is computed by dividing the net loss applicable to common shareholders by the weighted average number of shares of common stock outstanding for the period. Diluted loss per share is computed by dividing the loss applicable to common shareholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued, using the treasury stock method. Due to the Company’s losses in the periods presented, the Company currently has no 0.01 nine September 30, 2018. |
Note 2 - Going Concern
Note 2 - Going Concern | 9 Months Ended |
Sep. 30, 2018 | |
Notes to Financial Statements | |
Going Concern [Text Block] | NOTE 2 CannaMED has not September 30, 2018, $61,114 $82,844. may The accompanying financial statements have been prepared assuming that the Company will continue as a going concern; however, the above condition raises substantial doubt about the Company's ability to do so. The financial statements do not may In order to maintain its current level of operations, the Company will require additional working capital from either cash flow from operations, loans from officers, or from the sale of its equity. However, the Company currently has no third |
Note 3 - Recent Accounting Pron
Note 3 - Recent Accounting Pronouncements | 9 Months Ended |
Sep. 30, 2018 | |
Notes to Financial Statements | |
New Accounting Pronouncements and Changes in Accounting Principles [Text Block] | NOTE 3 In March 2016, December 15, 2016, In February 2016, December 15, 2018, There are no |
Note 4 - Stockholders' Deficit
Note 4 - Stockholders' Deficit | 9 Months Ended |
Sep. 30, 2018 | |
Notes to Financial Statements | |
Stockholders' Equity Note Disclosure [Text Block] | NOTE 4 Preferred Stock - 20,000,000 $0.0001 no September 30, 2018 December 31, 2017. Common Stock - $ 0.0001 100,000,000 3,500,000 September 30, 2018 December 31, 2017. The current ownership structure is as follows: Common Shares Percent Mikhail Artamonov 3,000,000 86 % James McKillop 250,000 7 % James Cassidy 250,000 7 % 3,500,000 100 % |
Note 5 - Income Tax
Note 5 - Income Tax | 9 Months Ended |
Sep. 30, 2018 | |
Notes to Financial Statements | |
Income Tax Disclosure [Text Block] | NOTE 5 The Company has not not not. not. |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 9 Months Ended |
Sep. 30, 2018 | |
Accounting Policies [Abstract] | |
Basis of Accounting, Policy [Policy Text Block] | Basis of Presentation The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Intercompany accounts and transactions have been eliminated. |
Use of Estimates, Policy [Policy Text Block] | Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that may |
Cash and Cash Equivalents, Policy [Policy Text Block] | Income Taxes CannaMED accounts for income taxes in accordance with ASC 740, 740” not ASC 740 740 not not |
Income Tax, Policy [Policy Text Block] | Cash and Cash Equivalents Cash and cash equivalents includes all highly liquid instruments with an original maturity of six September 30, 2018. not September 30, 2018 December 31, 2017. |
Concentration Risk, Credit Risk, Policy [Policy Text Block] | Concentration of Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high quality banking institutions. The Company did not September 30, 2018 December 31, 2017. |
Fair Value of Financial Instruments, Policy [Policy Text Block] | Fair Value of Financial Instruments The Company adopted ASC 820, 820 820 three three ● Level 1 ● Level 2 ● Level 3 The carrying value of cash, accounts payables and accrued expenses approximates their fair values due to their short-term maturities at September 30, 2018 December 31, 2017. |
Revenue Recognition, Policy [Policy Text Block] | Revenue Recognition Effective January 1, 2018, 606, Revenue from Contracts with Customers, 606 606, five no |
Earnings Per Share, Policy [Policy Text Block] | Net Loss Per Share Basic net loss per share is computed by dividing the net loss applicable to common shareholders by the weighted average number of shares of common stock outstanding for the period. Diluted loss per share is computed by dividing the loss applicable to common shareholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued, using the treasury stock method. Due to the Company’s losses in the periods presented, the Company currently has no 0.01 nine September 30, 2018. |
Note 4 - Stockholders' Deficit
Note 4 - Stockholders' Deficit (Tables) | 9 Months Ended |
Sep. 30, 2018 | |
Notes Tables | |
Schedule of Other Ownership Interests [Table Text Block] | Common Shares Percent Mikhail Artamonov 3,000,000 86 % James McKillop 250,000 7 % James Cassidy 250,000 7 % 3,500,000 100 % |
Note 1 - Basis of Presentatio_2
Note 1 - Basis of Presentation and Organization (Details Textual) - USD ($) | Aug. 25, 2015 | Aug. 24, 2015 | Sep. 30, 2018 | Sep. 30, 2017 | Sep. 30, 2018 | Sep. 30, 2017 | Dec. 31, 2017 |
Equity Method Investment, Ownership Percentage | 100.00% | 100.00% | |||||
Common Stock, Shares, Outstanding, Ending Balance | 3,500,000 | 3,500,000 | 3,500,000 | ||||
Cash Equivalents, at Carrying Value, Total | $ 0 | $ 0 | $ 0 | ||||
Cash, Uninsured Amount | $ 0 | $ 0 | $ 0 | ||||
Weighted Average Number Diluted Shares Outstanding Adjustment, Total | 0 | ||||||
Earnings Per Share, Basic and Diluted, Total | $ (0.01) | $ (0.01) | |||||
Mikhail Artamonov [Member] | |||||||
Stock Issued During Period, Shares, New Issues | 3,000,000 | 19,500,000 | |||||
Stock Issued During Period, Value, New Issues | $ 75,000 | ||||||
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum | 98.00% | ||||||
Equity Method Investment, Ownership Percentage | 86.00% | 7.00% | |||||
Stock Redeemed or Called During Period, Shares | 19,500,000 | ||||||
Common Stock, Shares, Outstanding, Ending Balance | 3,500,000 | 20,000,000 | |||||
Sale of Stock, Price Per Share | $ 0.0001 |
Note 2 - Going Concern (Details
Note 2 - Going Concern (Details Textual) - USD ($) | Sep. 30, 2018 | Dec. 31, 2017 |
Working Capital | $ (61,114) | |
Retained Earnings (Accumulated Deficit), Ending Balance | $ (82,844) | $ (60,814) |
Note 4 - Stockholders' Defici_2
Note 4 - Stockholders' Deficit (Details Textual) - $ / shares | Sep. 30, 2018 | Dec. 31, 2017 |
Preferred Stock, Shares Authorized | 20,000,000 | 20,000,000 |
Preferred Stock, Par or Stated Value Per Share | $ 0.0001 | $ 0.0001 |
Preferred Stock, Shares Issued, Total | 0 | 0 |
Common Stock, Par or Stated Value Per Share | $ 0.0001 | $ 0.0001 |
Common Stock, Shares Authorized | 100,000,000 | 100,000,000 |
Common Stock, Shares, Issued, Total | 3,500,000 | 3,500,000 |
Common Stock, Shares, Outstanding, Ending Balance | 3,500,000 | 3,500,000 |
Note 4 - Stockholders' Defici_3
Note 4 - Stockholders' Deficit - Ownership Structure (Details) - shares | Sep. 30, 2018 | Dec. 31, 2017 |
Common stock, shares issued (in shares) | 3,500,000 | 3,500,000 |
Percent | 100.00% | |
Mikhail Artamonov [Member] | ||
Common stock, shares issued (in shares) | 3,000,000 | |
Percent | 86.00% | |
James Mckillop [Member] | ||
Common stock, shares issued (in shares) | 250,000 | |
Percent | 7.00% | |
James Cassidy [Member] | ||
Common stock, shares issued (in shares) | 250,000 | |
Percent | 7.00% |
Note 5 - Income Tax (Details Te
Note 5 - Income Tax (Details Textual) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2018 | Sep. 30, 2017 | Sep. 30, 2018 | Sep. 30, 2017 | |
Income Tax Expense (Benefit), Total | $ 0 | $ 0 | $ 0 |